Perspective Therapeutics (NASDAQ:CATX) Given Average Rating of “Buy” by Analysts

Perspective Therapeutics (NASDAQ:CATX) has received an average rating of “Buy” from the six analysts that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have issued a report on the stock in the last year is $11.1667.

CATX has been the subject of a number of research analyst reports. BTIG Research reissued a “buy” rating and set a $14.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, January 13th. UBS Group dropped their target price on Perspective Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, November 21st. B. Riley lowered their price objective on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Friday. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Perspective Therapeutics in a research report on Friday.

Institutional Investors Weigh In On Perspective Therapeutics

Large investors have recently made changes to their positions in the stock. R Squared Ltd acquired a new stake in Perspective Therapeutics in the fourth quarter valued at $44,000. Auctus Advisors LLC bought a new position in Perspective Therapeutics during the fourth quarter worth about $87,000. Taylor & Morgan Wealth Management LLC increased its position in Perspective Therapeutics by 6.6% during the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 97,000 shares of the company’s stock worth $267,000 after buying an additional 6,000 shares during the last quarter. Trueblood Wealth Management LLC raised its stake in Perspective Therapeutics by 72.4% in the fourth quarter. Trueblood Wealth Management LLC now owns 119,061 shares of the company’s stock valued at $327,000 after buying an additional 50,000 shares during the period. Finally, UBS Group AG lifted its position in shares of Perspective Therapeutics by 44.5% in the fourth quarter. UBS Group AG now owns 926,331 shares of the company’s stock valued at $2,547,000 after buying an additional 285,188 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Stock Down 9.4%

Shares of NASDAQ:CATX traded down $0.40 during midday trading on Friday, hitting $3.86. The company’s stock had a trading volume of 5,292,474 shares, compared to its average volume of 5,384,544. The stock’s 50 day moving average is $2.61. The firm has a market capitalization of $286.94 million, a PE ratio of -4.29 and a beta of 1.18. Perspective Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $6.16.

Perspective Therapeutics Company Profile

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.